In the context of COPD, p38 inhibition has been observed to effectively mitigate inflammation and oxidative stress in the pulmonary and muscular tissues of affected individuals, which are closely associated with airflow restriction, respiratory distress, and reduced physical tolerance [55, 174]. Here, MAPK1 is linked to chronic obstructive pulmonary disease.